A very interesting ongoing phase 1/2 clinical trial is investigating the efficiency of an IL-2 pegylated molecule (Bempegaldesleukin) in combination with nivolumab for the treatment of melanoma, with promising primary results [32]. The gene discussed is IL2; the disease is melanoma.